Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Genprex Inc. GNPX

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO Presenting at the 2020 LD Micro Virtual Conference

Posted on March 4, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, this morning announced that the company’s chairman and chief executive officer Rodney Varner will be leading a presentation and answering questions from … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Present at the Third Annual LD Micro Virtual Conference

Posted on March 3, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that it will present at the third annual LD Micro Virtual Conference at 1:40 p.m. EST on Wednesday, March 4. … Continue reading →

Posted in Genprex, Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $17,500,000 Common Stock Offering At-The-Market

Posted on February 20, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, on Wednesday announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh for Potentially Curative Gene Therapy Candidate for Diabetes

Posted on February 11, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced its entry into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that … Continue reading →

Posted in Genprex, Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Meets Nasdaq Minimum Bid Price Requirement, Regains Compliance

Posted on February 6, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its February 4, 2020 receipt of notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Focus Clinical Efforts on Oncoprex(TM) in Combination with Osimertinib for Treatment of Non-Small Cell Lung Cancer

Posted on February 5, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provided a clinical update and focus for its Oncoprex(TM) immunogene therapy program for 2020. According to … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at NobleCon16 Investor Conference

Posted on February 3, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that it will present at the Noble Capital Markets 16th Annual Investor Conference. Genprex’s presentation … Continue reading →

Posted in Genprex, Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Independent Research Findings on TUSC2 as a Potential Target and Biomarker for Thyroid Carcinoma

Posted on January 29, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that, in a recent study, independent researchers reported that TUSC2, a tumor suppressor gene and … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Closes $8M At-The-Market Offering

Posted on January 28, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced the closing of its common stock … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $8M Common Stock Offering At-The-Market

Posted on January 23, 2020 by MissionIR

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced its entry into securities purchase agreements … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment